Photo by aaronburden from unsplash
PERSIST was a prospective, non‐interventional, long‐term, German multicentre study of patients with moderate‐to‐severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)‐23, in… Click to show full abstract
PERSIST was a prospective, non‐interventional, long‐term, German multicentre study of patients with moderate‐to‐severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)‐23, in a real‐world setting.
Keywords:
study patients;
non interventional;
german multicentre;
persist;
real world
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!